ABBV240705C215000
- 0.01
- 0.000.00%
AbbVie Newsroom
AbbVie Names Robert A. Michael CEO; Richard A. Gonzalez To Become Executive Chairman
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael Joins AbbVie Board of DirectorsNORTH CHICAGO, Ill., July 1, 2024 /PRNewswi
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
Express News | Robert a. Michael Assumes Role as Abbvie Chief Executive Officer
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael Joins AbbVie Board of DirectorsNORTH CHICAGO, Ill., July 1, 2024 /PRNewswi
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
AbbVie, Genmab Blood Cancer Therapy Endorsed in EU
AbbVie (ABBV.US) has reached a $250 million acquisition agreement and obtained a potential first-in-class therapy.
Recently, AbbVie (ABBV.US) announced the acquisition of Celsius Therapeutics for a total consideration of USD 250 million.
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
AbbVie Completes Acquisition of Celsius Therapeutics for $250m
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
AbbVie (ABBV) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion on a conditional marketing authorization of Tepkinly as a
AbbVie: CHMP Adopts Positive Opinion Recommending Conditional Marketing Authorization Of Epcoritamab
Express News | Abbvie - European Commission Decision on This Indication for Epcoritamab Is Anticipated Later This Year
Express News | Abbvie Receives Positive Chmp Opinion for Epcoritamab (Tepkinly®) for the Treatment of Adults With Relapsed/Refractory Follicular Lymphoma
Health Care Stocks Fall With Broad Market -- Health Care Roundup
Health-care company stocks fell as the broader market pulled back on the latest round of economic reports. AbbVie said it has acquired clinical-stage biotechnology company Celsius Therapeutics for $2
Coherus to Divest Biosimilar Against AbbVie's Humira for $40M
Sector Update: Health Care Stocks Decline in Afternoon Trading
Health care stocks fell Thursday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down 0.4%. The iShares Biotechnology ETF (IBB) eased 0.1%. In corporat
Wells Fargo Updated Its Signature Picks, With Vertex Pharma and AvalonBay as Adds
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
On Wednesday, the FDA approved Epkinly (epcoritamab-bysp) as the first and only T-cell-engaging bispecific antibody administered subcutaneously for adults with relapsed or refractory follicular lympho
Express News | AbbVie Shares Are Trading Lower After the Company Announced the Acquisition of Celsius Therapeutics